All In Biotech

Drug Trial Radar · NCT06468228

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,400

Actual

Start

Jun 27, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS . Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms. In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous injections of lutikizumab every week for 16 weeks, then either every week or every other week for 20 weeks. Period 3 is the Long Term Extentsion (LTE) and through Week 68, participants will continue to receive lutikizumab SC using the same assigned dosing regimen from the end of Period 2 for 16 weeks followed by open-label lutikizumab EOW for 140 weeks. Participants in the US that complete Periods 1 \& 2 will have the option to enroll in a 156-week open-label Sub-Study that will assess the long term safety and efficacy of lutikizumab in a prefilled pen. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • LutikizumabDrug

    Subcutaneous injection

  • PlaceboDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75Time frame: At Week 16
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Week 62

Locations

279 sites in 44 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center /ID# 263795

    Birmingham, Alabama

  • Medical Dermatology Specialists /ID# 263394

    Phoenix, Arizona

  • Banner University Medicine Dermatology /ID# 263557

    Tucson, Arizona

  • Dermatology Trial Associates /ID# 264587

    Bryant, Arkansas

  • Arkansas Research Trials /ID# 263901

    North Little Rock, Arkansas

  • Private Practice - Dr. Tooraj Raoof /ID# 263756

    Encino, California

  • Dermatology Research Associates - Los Angeles /ID# 263765

    Los Angeles, California

  • Stanford University School of Medicine - Redwood City /ID# 263711

    Redwood City, California

  • Norcal Clinical Research /ID# 279008

    Rocklin, California

  • Integrative Skin Science and Research /ID# 264600

    Sacramento, California

  • Clinical Trials Research Institute /ID# 263743

    Thousand Oaks, California

  • Yale University School of Medicine /ID# 263695

    New Haven, Connecticut

  • Clearlyderm Dermatology - West Boca /ID# 265023

    Boca Raton, Florida

  • Apex Clinical Trials /ID# 263815

    Brandon, Florida

  • TrueBlue Clinical Research - Brandon /ID# 265041

    Brandon, Florida

  • Florida Academic Dermatology Center /ID# 263834

    Coral Gables, Florida

  • Direct Helpers Research Center /ID# 278343

    Hialeah, Florida

  • Skin Care Research - Hollywood /ID# 263805

    Hollywood, Florida

  • Gsi Clinical Research /ID# 263827

    Margate, Florida

  • Sullivan Dermatology /ID# 263511

    Miami, Florida

  • Vitalia Medical Research /ID# 278321

    North Palm Beach, Florida

  • Renstar Medical Research - Ocala - Northeast 1st Avenue /ID# 263842

    Ocala, Florida

  • Skin Care Research - Tampa /ID# 263819

    Tampa, Florida

  • Advanced Clinical Research Institute - Tampa /ID# 263808

    Tampa, Florida

  • University of South Florida /ID# 269624

    Tampa, Florida

  • Alliance Clinical Research of Tampa /ID# 264594

    Tampa, Florida

  • TruDerm Research /ID# 278217

    Wellington, Florida

  • Centricity Research Columbus Dermatology /ID# 266530

    Columbus, Georgia

  • Cleaver Medical Group Dermatology /ID# 263845

    Dawsonville, Georgia

  • Treasure Valley Medical Research /ID# 263671

    Boise, Idaho

  • DeNova Research /ID# 264593

    Chicago, Illinois

  • Northwestern University Feinberg School of Medicine /ID# 265007

    Chicago, Illinois

  • Arlington Dermatology /ID# 263410

    Rolling Meadows, Illinois

  • Dawes Fretzin /ID# 264601

    Indianapolis, Indiana

  • Dermatology Partners of Leawood /ID# 263533

    Leawood, Kansas

  • Equity Medical, LLC /ID# 268590

    Bowling Green, Kentucky

  • Dermatology Specialists Research (DS Research) - Kentucky /ID# 263343

    Louisville, Kentucky

  • Tulane University School of Medicine /ID# 263899

    New Orleans, Louisiana

  • Beth Israel Deaconess Medical Center /ID# 263709

    Boston, Massachusetts

  • UMass Memorial Medical Center - Lake Avenue North /ID# 274149

    Worcester, Massachusetts

Showing 40 of 279 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.